ArticleBMC global and public health2025
Experience with the mobile health application 'mSaada' to facilitate home-based human papillomavirus testing in Western Kenya.
Article in BMC global and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCervical cancer screening using human papillomavirus (HPV) DNA testing is an essential component of prevention efforts. Countries with limited health care infrastructure need innovative strategies to make HPV-based screening feasible. Our team developed a mobile phone application, mSaada, to facilitate counseling, data collection, and client follow-up for HPV-based cervical cancer screening in western Kenya.
methodsCommunity health promoters (CHPs) working in Kisumu County underwent training in mSaada-assisted HPV-based screening before offering testing via self-collection during routinely scheduled home visits. After each visit, CHPs filled out a questionnaire to capture factors interrupting the home visits, including technology challenges. HPV results and follow-up information were provided directly to women by text or home visit and put into their clinic records. Treatment with thermal ablation was offered at their local health facilities, free of charge. All CHPs completed an mSaada usability survey and focus group discussion at completion of the pilot.
resultsTwenty-two CHPs performed screening between October 2023 and June 2024. Of the 1118 women approached, 964 (86%) agreed to screen. Within 3 months after the screening period ended, 116 out of 218 women (53%) who tested positive for HPV completed follow-up treatment. Device or mSaada issues were minimal, with the most common being charging problems, slow mSaada performance, and quick response (QR) code scanner malfunctions. Usability scores indicated high satisfaction with mSaada (mean 4.4/5).
conclusionsmSaada was a useful tool to facilitate HPV-based screening during home visits. Workflow observations and qualitative data helped identify specific improvements in the workflow, device quality, and app design to improve impact and sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.